久久高清毛片,成人短视频在线观看免费,成人毛片一级,丰满少妇久久久,97av视频,亚洲老司机av,我要看高清av

產(chǎn)品分類導(dǎo)航
2025制藥工業(yè)深圳展
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management
Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management

Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management

更新時間:2025-06-20

價格:  元/個
CAS號: 910463-68-2
藥典: 中國藥典,企業(yè)標準
級別: injection
立即詢盤
收藏
產(chǎn)品詳情
產(chǎn)品關(guān)鍵詞: GLP-1 Agonist,Type 2 Diabetes Treatment,Weight Loss Therapy,Once- DWeeklyosing,Long-Acting Medication
是否為生產(chǎn)商:
產(chǎn)品包裝規(guī)格: 2mg/Ampoule 10mg/Ampoule 15mg/Ampoule 10Ampoules/Box
主要銷售市場: 中國,北美洲,中/南美洲,西歐,東歐,大洋洲,亞洲,中東,非洲
產(chǎn)品描述:


Mechanism of Action

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the effects of endogenous GLP-1. It works through several key mechanisms:

  1. Glucose-Dependent Insulin Secretion: Semaglutide stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner, enhancing glucose homeostasis.
  2. Inhibition of Glucagon Secretion: It reduces the secretion of glucagon from pancreatic α-cells, decreasing hepatic gluconeogenesis and maintaining stable blood glucose levels.
  3. Delayed Gastric Emptying: Semaglutide slows down gastric emptying, which helps reduce postprandial blood glucose spikes and contributes to a feeling of satiety.
  4. Appetite Regulation: By acting on the central nervous system, semaglutide activates anorexigenic signaling pathways, reducing food intake and promoting weight loss.
  5. Anti-Inflammatory and Antioxidant Effects: Semaglutide modulates inflammation and oxidative stress through pathways such as AMPK/SIRT1, reducing the activity of pro-inflammatory factors like NF-κB.

Applications

  1. Type 2 Diabetes Management: Semaglutide is used to improve glycemic control in adults with type 2 diabetes mellitus.
  2. Weight Management: It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
  3. Cardiovascular Risk Reduction: Semaglutide has been shown to reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease.

Dosage Instructions

  1. Initial Dose: Start with a 0.25 mg subcutaneous injection once weekly for the first 4 weeks.
  2. Maintenance Dose: After 4 weeks, increase the dose to 0.5 mg once weekly. If additional glycemic control is needed, the dose can be increased to 1 mg once weekly.
  3. Injection Instructions: Administer semaglutide subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and resume the regular schedule.

Storag

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
上海浦津林州制藥有限公司
注冊資本
聯(lián)系人
聯(lián)系電話
查看聯(lián)系方式
快速詢盤
詢盤主題
請輸入詢盤主題
詢盤信息
請輸入詢盤信息
滑動驗證
請完成滑塊驗證
快速發(fā)送詢盤
CPHI制藥在線為您找到Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management 價格、Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management 詳細參數(shù)、Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management 相關(guān)產(chǎn)品、Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management 供應(yīng)商等信息,想了解當前Semaglutide for Weight Loss: Harnessing GLP-1 for Effective Obesity Management 最新報價,請聯(lián)系上海浦津林州制藥有限公司。
2006-2025 上海博華國際展覽有限公司版權(quán)所有(保留一切權(quán)利) 滬ICP備05034851號-57